Latest Revenue Guidance News

Pureprofile has reported record first-half FY26 results, driven by strong international expansion and AI-powered platform growth, prompting an upgrade to its full-year revenue guidance.

Pureprofile Limited has upgraded its FY26 revenue guidance after a record first half, driven by strong international growth and a booming platform business. The Rest of World segment now outpaces ANZ, signalling a major shift in the company’s geographic footprint.

Change Financial has reported a robust first half of FY26, with revenue and EBITDA surpassing expectations, prompting an upgraded full-year guidance and signalling a key milestone in cash flow positivity.

Cogstate Ltd has reported a remarkable 105% surge in clinical trial sales contracts for the first half of 2026, surpassing revenue guidance and signalling a more diversified and resilient business model.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

Vinyl Group Ltd has reported a landmark quarter with record cash receipts up 80% quarter-on-quarter and its first operating cash flow positive result, signalling a turning point for the music and culture company.

Amaero Ltd has reported a remarkable 366% increase in revenue for the first half of FY2026, alongside key capital investments and formal validation from the US Navy, signalling a strong move towards scaled commercial production.

Amaero Ltd has lowered its FY2026 revenue guidance due to delayed U.S. government contracts but reports strong contracted revenue and a robust cash position heading into 2026.

AVITA Medical reported solid 11% revenue growth in 2025 and secured a $60 million credit facility to fuel its next phase of expansion, projecting up to 19% revenue growth in 2026.

EBR Systems reported a doubling of WiSE System implants in Q4 FY2025 alongside the launch of key clinical studies and preliminary revenue guidance, signalling strong commercial and clinical momentum.

Weebit Nano has raised its FY26 revenue guidance to a minimum of $10 million following the signing of multiple IP licensing agreements with semiconductor fabs and product companies.

Nick Scali Limited has upgraded its first half FY26 revenue and profit guidance, citing stronger than expected sales growth in Australia and New Zealand.